Bank of New York Mellon’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $706K | Sell |
619,149
-31,702
| -5% | -$37.7K | ﹤0.01% | 3569 |
|
|
2026
Q1 | $905K | Sell |
650,851
-16,056
| -2% | -$22.1K | ﹤0.01% | 3269 |
|
|
2025
Q4 | $1.07M | Sell |
666,907
-12,335
| -2% | -$25.8K | ﹤0.01% | 3195 |
|
|
2025
Q3 | $1.85M | Buy |
679,242
+63,641
| +10% | +$212K | ﹤0.01% | 2843 |
|
|
2025
Q2 | $2.24M | Buy |
615,601
+122,008
| +25% | +$335K | ﹤0.01% | 2688 |
|
|
2025
Q1 | $948K | Sell |
493,593
-3,954
| -0.8% | -$8.07K | ﹤0.01% | 3099 |
|
|
2024
Q4 | $945K | Buy |
497,547
+27,839
| +6% | +$48.3K | ﹤0.01% | 3194 |
|
|
2024
Q3 | $620K | Sell |
469,708
-134,843
| -22% | -$180K | ﹤0.01% | 3393 |
|
|
2024
Q2 | $617K | Buy |
604,551
+585,789
| +3,122% | +$724K | ﹤0.01% | 3462 |
|
|
2024
Q1 | $34.3K | Sell |
18,762
-53,069
| -74% | -$84.8K | ﹤0.01% | 4101 |
|
|
2023
Q4 | $89.1K | Buy |
71,831
+1
| +0% | +$1 | ﹤0.01% | 4108 |
|
|
2023
Q3 | $81.9K | Sell |
71,830
-6
| -0% | -$8 | ﹤0.01% | 4108 |
|
|
2023
Q2 | $65.7K | Hold |
71,836
| – | – | ﹤0.01% | 4133 |
|
|
2023
Q1 | $40.3K | Hold |
71,836
| – | – | ﹤0.01% | 4228 |
|
|
2022
Q4 | $41.4K | Hold |
71,836
| – | – | ﹤0.01% | 4267 |
|
|
2022
Q3 | $23K | Hold |
71,836
| – | – | ﹤0.01% | 4432 |
|
|
2022
Q2 | $26K | Sell |
71,836
-567,047
| -89% | -$238K | ﹤0.01% | 4462 |
|
|
2022
Q1 | $459K | Buy |
638,883
+14,038
| +2% | +$30K | ﹤0.01% | 3758 |
|
|
2021
Q4 | $1.41M | Buy |
624,845
+33,016
| +6% | +$90K | ﹤0.01% | 3188 |
|
|
2021
Q3 | $1.7M | Buy |
591,829
+29,674
| +5% | +$84.7K | ﹤0.01% | 3085 |
|
|
2021
Q2 | $2.13M | Sell |
562,155
-34,074
| -6% | -$115K | ﹤0.01% | 2944 |
|
|
2021
Q1 | $2.02M | Sell |
596,229
-61,682
| -9% | -$222K | ﹤0.01% | 2918 |
|
|
2020
Q4 | $1.84M | Buy |
657,911
+79,885
| +14% | +$233K | ﹤0.01% | 2898 |
|
|
2020
Q3 | $1.45M | Sell |
578,026
-53,282
| -8% | -$468K | ﹤0.01% | 2879 |
|
|
2020
Q2 | $8.57M | Buy |
631,308
+40,206
| +7% | +$416K | ﹤0.01% | 1924 |
|
|
2020
Q1 | $4.48M | Sell |
591,102
-101,256
| -15% | -$788K | ﹤0.01% | 2125 |
|
|
2019
Q4 | $4.38M | Buy |
692,358
+23,801
| +4% | +$113K | ﹤0.01% | 2402 |
|
|
2019
Q3 | $2.62M | Sell |
668,557
-4,317
| -0.6% | -$18.5K | ﹤0.01% | 2603 |
|
|
2019
Q2 | $3.26M | Buy |
672,874
+118,881
| +21% | +$676K | ﹤0.01% | 2547 |
|
|
2019
Q1 | $4.54M | Buy |
553,993
+5,398
| +1% | +$37K | ﹤0.01% | 2373 |
|
|
2018
Q4 | $3.03M | Buy |
548,595
+333,569
| +155% | +$2.61M | ﹤0.01% | 2536 |
|
|
2018
Q3 | $1.9M | Buy |
215,026
+306
| +0.1% | +$2.74K | ﹤0.01% | 2864 |
|
|
2018
Q2 | $2.14M | Buy |
214,720
+14,089
| +7% | +$141K | ﹤0.01% | 2809 |
|
|
2018
Q1 | $1.91M | Sell |
200,631
-50,762
| -20% | -$710K | ﹤0.01% | 2832 |
|
|
2017
Q4 | $3.74M | Buy |
251,393
+27,408
| +12% | +$455K | ﹤0.01% | 2491 |
|
|
2017
Q3 | $4.41M | Buy |
223,985
+24,167
| +12% | +$372K | ﹤0.01% | 2394 |
|
|
2017
Q2 | $2.87M | Buy |
199,818
+53,012
| +36% | +$672K | ﹤0.01% | 2626 |
|
|
2017
Q1 | $1.35M | Sell |
146,806
-976
| -0.7% | -$9.53K | ﹤0.01% | 3079 |
|
|
2016
Q4 | $1.54M | Buy |
147,782
+20,325
| +16% | +$175K | ﹤0.01% | 3020 |
|
|
2016
Q3 | $1.15M | Sell |
127,457
-2,518
| -2% | -$21.4K | ﹤0.01% | 3095 |
|
|
2016
Q2 | $971K | Buy |
129,975
+9,982
| +8% | +$87.1K | ﹤0.01% | 3155 |
|
|
2016
Q1 | $1.08M | Sell |
119,993
-29,370
| -20% | -$238K | ﹤0.01% | 3007 |
|
|
2015
Q4 | $1.93M | Buy |
149,363
+3,213
| +2% | +$32.8K | ﹤0.01% | 2733 |
|
|
2015
Q3 | $1.41M | Buy |
146,150
+74,596
| +104% | +$685K | ﹤0.01% | 2963 |
|
|
2015
Q2 | $736K | Buy |
71,554
+36,640
| +105% | +$313K | ﹤0.01% | 3494 |
|
|
2015
Q1 | $388K | Sell |
34,914
-25
| -0.1% | -$266 | ﹤0.01% | 3705 |
|
|
2014
Q4 | $406K | Buy |
34,939
+4,861
| +16% | +$69.7K | ﹤0.01% | 3695 |
|
|
2014
Q3 | $665K | Buy |
30,078
+1,462
| +5% | +$33.6K | ﹤0.01% | 3518 |
|
|
2014
Q2 | $795K | Buy |
+28,616
| New | +$689K | ﹤0.01% | 3428 |
|
Other funds holding AKBA
HWAM
N
CL
PAM
VEA
Bank of New York Mellon's AKBA Position: Q2 2026 in Review
Bank of New York Mellon reduced its Akebia Therapeutics (AKBA) stake by 4.9% in Q2 2026, selling an estimated $37.7K and leaving 619,149 shares worth $706K. The position accounts for ﹤0.01% of the portfolio, ranked #3569.
Bank of New York Mellon first reported a position in AKBA in Q2 2014 and has held it in 49 quarters since. The position peaked at $8.57M in Q2 2020. 82 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.
- Bank of New York Mellon held 619,149 shares of Akebia Therapeutics worth $706K as of Q2 2026.
- Bank of New York Mellon sold 31,702 Akebia Therapeutics shares in Q2 2026, an estimated $37.7K.
- Akebia Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3569 holding.
- Bank of New York Mellon first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 49 quarters since.
- Bank of New York Mellon's Akebia Therapeutics position peaked at $8.57M in Q2 2020.
- 82 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.